Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
14.45
+0.20 (1.40%)
Jul 16, 2025, 1:52 PM - Market open

Company Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.

The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases.

The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept.

Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics, Inc.
Keros Therapeutics logo
CountryUnited States
Founded2015
IPO DateApr 8, 2020
IndustryBiotechnology
SectorHealthcare
Employees169
CEOJasbir Seehra

Contact Details

Address:
1050 Waltham Street, Suite 302
Lexington, Massachusetts 02421
United States
Phone617 314 6297
Websitekerostx.com

Stock Details

Ticker SymbolKROS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001664710
CUSIP Number492327101
ISIN NumberUS4923271013
Employer ID81-1173868
SIC Code2834

Key Executives

NamePosition
Dr. Jasbir S. Seehra Ph.D.Chief Executive Officer and Chair of the Board
Christopher Rovaldi M.Sc.President and Chief Operating Officer
Keith C. Regnante MBAChief Financial Officer
Dr. Yung H. Chyung M.D.Chief Medical Officer
Esther Cho J.D.Senior Vice President, General Counsel and Secretary
Robin WagnerSenior Vice President of Human Resources
John Oram M.B.A.Senior Vice President of Program and Portfolio Management

Latest SEC Filings

DateTypeTitle
Jul 15, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
Jun 6, 20258-KCurrent Report
May 29, 20258-KCurrent Report
May 27, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 19, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 19, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 19, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 14, 2025SCHEDULE 13GFiling
May 12, 2025SCHEDULE 13D/AFiling